Evercore ISI raised the firm’s price target on GE HealthCare to $102 from $98 and keeps an Outperform rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends for are on track for improvement in the second half, but the debate is around the instrument outlook and China stimulus given the recent run in stocks in the space, the analyst tells investors in MedTech and Tools Q3 preview.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GEHC:
- GE HealthCare price target raised to $102 from $100 at Stifel
- GE HealthCare announces FDA approval of Flyrcado injection PET radiotracer
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Starbucks upgraded, Hershey downgraded: Wall Street’s top analyst calls
- GE HealthCare downgraded to Sell from Neutral at UBS